Adalimumab
Brand names: Humira · Active ingredient: Adalimumab-Ryvk
In short: Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combinat
What is Adalimumab used for?
Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate.
Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs.
Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
Limitations of Use
The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers
. …
âš Boxed warning (FDA's strongest warning)
SERIOUS INFECTIONS
Patients treated with adalimumab products, including
Adalimumab-ryvk, are at increased risk for developing serious infections that may lead to hospitalization or death
. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue
Adalimumab-ryvk if a patient develops a serious infection or sepsis.
Reported infections include:
Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before
Adalimumab-ryvk use and during therapy. Initiate treatment for latent TB prior to
Adalimumab-ryvk use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.
Carefully consider the risks and benefits of treatment with
Adalimumab-ryvk prior to initiating therapy in patients with chronic or recurrent infection. …
Adalimumab dosage
Prior to initiating Adalimumab-ryvk and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection
.
The recommended subcutaneous dosage of Adalimumab-ryvk for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS)
is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with Adalimumab-ryvk. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of Adalimumab-ryvk to 40 mg every week or 80 mg every other week.
The recommended subcutaneous dosage of Adalimumab-ryvk for pediatric patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis
,based on weight, is shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with Adalimumab-ryvk.
Pediatric Weight
(2 Years of Age and Older) | Recommended Dosage
15 kg (33 lbs) to less than 30 kg (66 lbs) | 20 mg every other week
30 kg (66 lbs) and greater | 40 mg every other week
There is no dosage form for Adalimumab-ryvk that allows weight-based dosing for pediatric patients below 15 kg.
Adalimumab products have not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 years of age or in patients with a weight below 10 kg.
Subcutaneous Adult Dosage Regimen
The recommended subcutaneous dosage of Adalimumab-ryvk for adult patients with moderately to severely active Crohn’s disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with Adalimumab-ryvk. Azathioprine, 6-mercaptopurine (6-MP)
or MTX may be continued during treatment with Adalimumab-ryvk if necessary. …
How to take Adalimumab — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (
Medication Guideand
Instructions for Use).
Infections
Inform patients that Adalimumab-ryvk may lower the ability of their immune system to fight infections. Instruct patients of the importance of contacting their doctor if they develop any symptoms of infection, including tuberculosis, invasive fungal infections, and reactivation of hepatitis B virus infections
.
Malignancies
Counsel patients about the risk of malignancies while receiving Adalimumab-ryvk
.
Hypersensitivity Reactions
Advise patients to seek immediate medical attention if they experience any symptoms of severe hypersensitivity reactions
.
Other Medical Conditions
Advise patients to report any signs of new or worsening medical conditions such as congestive heart failure, neurological disease, autoimmune disorders, or cytopenias. Advise patients to report any symptoms suggestive of a cytopenia such as bruising, bleeding, or persistent fever
.
Instructions on Injection Technique
Inform patients that the first injection is to be performed under the supervision of a qualified health care professional. …
Warnings & precautions
Do not take this medicine if: None.
Patients treated with adalimumab products, including Adalimumab-ryvk, are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.
The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant use of Adalimumab-ryvk and these biologic products is not recommended in the treatment of patients with RA
.
Treatment with Adalimumab-ryvk should not be initiated in patients with an active infection, including localized infections. Patients 65 years of age and older, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. Consider the risks and benefits of treatment prior to initiating therapy in patients:
with chronic or recurrent infection;
who have been exposed to tuberculosis;
with a history of an opportunistic infection;
who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or
with underlying conditions that may predispose them to infection. …
Adalimumab side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Serious Infections
Malignancies
Hypersensitivity Reactions
Hepatitis B Virus Reactivation
Neurologic Reactions
Hematological Reactions
Heart Failure
Autoimmunity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most common adverse reaction with adalimumab was injection site reactions. In placebo-controlled trials, 20% of subjects treated with adalimumab developed injection site reactions (erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of subjects receiving placebo. Most injection site reactions were described as mild and generally did not necessitate drug discontinuation.
The proportion of subjects who discontinued treatment due to adverse reactions during the double-blind, placebo-controlled portion of studies in subjects with RA (i.e., Studies RA-I, RA-II, RA-III and RA-IV) was 7% for subjects taking adalimumab and 4% for placebo-treated subjects. The most common adverse reactions leading to discontinuation of adalimumab in these RA studies were clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%). …
Drug interactions
Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either Adalimumab-ryvk or MTX
.
In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of Adalimumab-ryvk with abatacept or anakinra is not recommended in patients with RA
. A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker. There is insufficient information regarding the concomitant use of Adalimumab-ryvk and other biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS, and UV. Concomitant administration of Adalimumab-ryvk with other biologic DMARDS (e.g., anakinra and abatacept) or other TNF blockers is not recommended based upon the possible increased risk for infections and other potential pharmacological interactions.
Avoid the use of live vaccines with Adalimumab-ryvk
. …
About this medicine
Adalimumab-ryvk is a tumor necrosis factor blocker. Adalimumab-ryvk is a recombinant human IgG1 monoclonal antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab-ryvk is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
Adalimumab-ryvk injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose, prefilled Adalimumab-ryvk autoinjector or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the autoinjector is a single-dose, 1 mL prefilled glass syringe. The solution of Adalimumab-ryvk is clear and colorless, with a pH of 5.0-5.6.
Each 80 mg/0.8 mL prefilled syringe or prefilled autoinjector delivers 0.8 mL (80 mg) of drug product. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID dce1590f-9e47-4c4d-9437-cfb18b779a75. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine